spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  crizotinib 

 HSMN NewsFeed - 14 Mar 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Mar 2021
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
Diagnostics Oncology FDA
 HSMN NewsFeed - 26 Feb 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 17 Jul 2017
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Jun 2017
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Diagnostics Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2014
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Oct 2012
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 May 2012
Ruga Corporation Expands Management Team to Advance Its Adaptive Response Therapeutics for Cancer Patients
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 6 Mar 2012
Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2011
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
Diagnostics Personalized Medicine Oncology FDA
 HSMN NewsFeed - 26 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.